One-stop CAR-T Therapy Development Platform

The use of CAR-T therapy has had a positive influence on the recovery of hematological malignancies such as leukemia and lymphoma. However, differing constraints that undermine CAR-T effectiveness within solid tumors. Protheragen's group of experts consists of top-tier scientists and professionals who strive to improve the current limitations of CAR-T therapy by providing a full range of services aimed at enhancing the efficiency of therapeutic and durability, extending the scope of services to all stages of CAR-T therapy development.

Introduction to CAR-T Therapy

CAR-T cell therapy is one of the nascent therapies that is concerned with the genetic alteration of the individual's T cells, enabling them to identify and destroy malignant cells. The CAR-T cells possess the ability to selectively and efficiently target and kill cancerous cells and can remain in the body for extended periods, thus delivering long-lasting anti-cancer effects. Some of the hematologic malignancies like B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL), and multiple myeloma have been successfully treated with CAR-T cell therapy. Apart from that, CAR T cell therapy is being used for the therapeutic of conditions other than cancer for example autoimmune diseases, fibrotic diseases, infectious diseases, etc.

Fig.1 Development of CARs. (Dabas, P., and Danda, A., 2023)

In recent times there have been many strides made in the area of CAR-T cell therapy which include newly developed next-generation CAR-T constructs as well as the use of newly discovered antigen targets.

• A standout improvement was the application of gene-editing techniques to improve the functionality of CAR-T cells.
• Another area of interest is the development of bi-specific CAR-T cell therapies and tandem CAR-T cell therapies.

Types of CAR-T Cell Therapy

Autologous CAR-T Cell Therapy

The existing technique of producing CAR-T cell therapy involves the extraction of T-cells from an individual, modifying their genetics, and allowing them to proliferate in the laboratory before injecting them back into the individual.

Off-the-Shelf CAR-T Cell Therapy

The off-the-shelf alternative utilizes T-cells obtained from healthy donors in an allogeneic manner. Hence by this method, the need to manufacture CAR-T cells on an individual basis for every individual is bypassed.

Our Services

Owing to our experience and know-how in developing cell therapies and with the availability of the advanced EndureCARTTM technological platform, Protheragen renders a full range of services to the developers of CAR-T cell therapy, including the design of CAR molecules, preparation of cells, and conducting phenotypic analysis, cell and animal model generation, and in vitro/in vivo efficacy studies. We design the whole process from ideas to commercialization of the products, considering your goals and needs for effective CAR-T cell therapy.

One-stop CAR-T Therapy Development Platform

CAR Design and Construction

• Target recognition and antibody development
• Design and construction of CARs
• CAR lentivirus preparation

CAR-T Cell Preparation

• T cell isolation and activation
• Viral or non-viral gene delivery

In Vitro Assay Services

• CAR expression validation
• CAR-T cell proliferation
• CAR-T cell cytotoxicity
• Cytokine detection

In Vivo Analysis Services

• Animal model construction
• Pharmacodynamic evaluation
• Viability and bio-distribution study of CAR-T cells
• Toxicity evaluation

Our Advantages

• Tailored Services
  Bespoke CAR-T therapy development services that address the specific requirements of each customer. So that each project is catered for individualized solutions.
• Advanced Platforms
  By applying EndureCART^TM technologies and modern methodologies we enable our clients to stay at the forefront in CAR-T therapy development.
• Extensive Disease Models
  The rich disease model serves as a tool for assessing CAR-T therapy in vitro and in vivo, thus refining approaches and ensuring better therapeutic outcomes.

When you partner with Protheragen, you have a partner who has the goal of building the future of CAR-T therapy with you. We provide the leading EndureCART^TM technology platform and comprehensive services and can work towards enabling novel cellular immunotherapies for the further development of CAR-T therapies. If you have any interest in our technology platform and services, please feel free to contact us.

For research use only, not for clinical use.